IMWG consensus on maintenance therapy in multiple myeloma

Overview of attention for article published in Blood, January 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source
twitter: 10 X users

patent: 10 patents
facebook: 1 Facebook page

Readers on

mendeley: 218 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 7 policy documents that reference this research output.

Pomalyst in combination with dexamethasone and bortezomib for Multiple Myeloma (second-line or beyond) – Details - Pomalidomide (Pomalyst) Bortezomib MM – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 15 Mar 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Ninlaro for Multiple Myeloma (2nd-beyond) – Details - Ixazomib (Ninlaro) Multiple Myeloma (2nd-beyond) – Final Clinical Guidance ReportG

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 30 Nov 2018

Ninlaro for Multiple Myeloma – Details - Ixazomib (Ninlaro) Multiple Myeloma - Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 16 Dec 2016

Kyprolis (with lenalidomide) for Multiple Myeloma – Details - Carfilzomib (Kyprolis) MM – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 11 Dec 2015

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity, including 3 additional policy documents.